Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior Pharmaceuticals, Inc. plans a private offering of $400,000,000 of convertible senior notes due March 15, 2031, with an option for initial purchasers to buy up to an additional $60,000,000.
The senior unsecured notes will pay semi-annual interest and may be converted in certain situations into cash and, if applicable, common stock. Indivior expects to use about $239 million of net proceeds plus about $102 million of cash on hand to repay and terminate its term loan and revolving credit facility, to use up to approximately $75 million to repurchase common shares from certain note purchasers at the notes’ pricing, and to apply the remainder to general corporate purposes.
Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley bought additional shares of the company in the open market. On March 6, 2026, he purchased 940 shares of Common Stock at an average price of $31.865 per share. Following this open‑market purchase, he directly owns 5,582 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. director Ryan Barbara reported an open-market purchase of common stock. On March 9, 2026, Ryan Barbara bought 31 shares of Indivior common stock at $32.56 per share. After this trade, the director directly owns 5,716 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. Chief Accounting Officer Anderson Woodrow D reported equity award vesting and related share movements on March 3, 2026. Performance stock units granted on March 3, 2023 vested at 76.6%, resulting in 18,364 common shares out of a 23,975 target amount, and restricted stock units also vested.
To cover tax withholding tied to these vestings, 8,283 and 2,682 common shares were disposed of at $31.98 per share through tax-withholding transactions, rather than open-market sales. After these derivative conversions and tax withholdings, the reporting person held 24,638 shares of common stock directly.
Indivior Pharmaceuticals, Inc. Chief Financial Officer Ryan Preblick reported equity award activity involving performance stock units and common stock. In 2024, 204,904 shares vested from performance stock units granted on March 3, 2021 and were subject to a further two-year holding period. On March 3, 2026, this holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations. On the same date, 86,949 shares of common stock vested from performance stock units granted on March 3, 2023 after performance conditions were determined to be met at 76.6% of a 113,510 share target. Each performance stock unit represents a contingent right to receive one share of common stock. After these transactions, Preblick held 317,292 shares of Indivior common stock directly.
Indivior Pharmaceuticals, Inc. Chief Legal Officer Jeffrey W. Burris reported the vesting of performance stock units on March 3, 2026. The units vested after performance conditions were determined to be met at 76.6%, resulting in 79,893 common shares vesting from a 104,300 target grant made on March 3, 2023. Each performance stock unit corresponded to one share of common stock. To cover tax withholding obligations from this vesting, 36,032 shares of common stock were disposed of at a price of $31.98 per share, leaving Burris with 71,518 directly owned common shares after these transactions.
Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder had performance stock units granted on March 3, 2023 vest on March 3, 2026 after performance conditions were determined to be met at 76.6%. This resulted in 101,544 shares of common stock vesting out of a 132,565 target amount, with each unit representing one share. To cover tax withholding related to this vesting, 45,797 shares of common stock were disposed of at $31.98 per share. Following these transactions, Heidbreder directly held 246,509 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. describes its transition to a U.S.-domiciled parent company and its core focus on treating opioid use disorder (OUD), led by long-acting injectable SUBLOCADE and sublingual SUBOXONE Film and SUBUTEX.
The company reports that the U.S. generated 85% of net revenues in 2025, driven mainly by SUBLOCADE, which delivered $856 million of 2025 global net sales versus $346 million from sublingual products. SUBLOCADE has treated more than 475,000 patients since approval and gained an FDA label expansion in 2025 enabling rapid initiation and more flexible injection sites.
Indivior highlights 2025 developments including CEO succession to Joseph Ciaffoni, inclusion in major U.S. equity indices, restructuring of R&D and Medical Affairs, and exit from several smaller Rest of World markets to concentrate on the U.S., Canada, Australia, France, and Germany. The company also outlines a pipeline featuring INDV-6001, a potential three‑month buprenorphine injection, and INDV-2000, a non‑opioid OUD candidate, both with Phase 2 studies completed in 2025 and results expected in 2026.
Indivior Pharmaceuticals, Inc. reported a strong fourth quarter and full-year 2025, driven by its long-acting opioid use disorder treatment SUBLOCADE. 2025 net revenue reached $1,239 million, up from $1,188 million, with total SUBLOCADE net revenue rising to $856 million from $756 million.
GAAP net income improved sharply to $210 million from $7 million, while non-GAAP net income increased to $320 million. Adjusted EBITDA grew to $428 million from $358 million, lifting the adjusted EBITDA margin to 35%. The company highlighted cost reductions and a simplified operating model following its U.S. domestication completed in January 2026.
For 2026, Indivior guides total net revenue of $1,125–$1,195 million and SUBLOCADE net revenue of $905–$945 million, with non-GAAP operating expenses of $430–$450 million and adjusted EBITDA of $535–$575 million. It expects about $300 million in cash flow from operations and has authorized a new $400 million share repurchase program while maintaining a low leverage ratio of 0.7x.
Indivior Pharmaceuticals, Inc. received a disclosure that a group of investment entities led by Madison Avenue International LP holds a significant minority stake in its ordinary shares. As of February 17, 2026, the group beneficially owned 6,280,502 ordinary shares.
This position represents approximately 5.0% of Indivior’s outstanding ordinary shares, based on 124,853,897 shares outstanding as of October 1, 2025. The reporting investors state that the shares were not acquired for the purpose of changing or influencing control of the company.